Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability. With no disease-modifying treatments available or on the horizon, oral non-steroidal anti-inflammatory ...
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Aubagio (teriflunomide; Genzyme) that includes revisions to the Contraindications, Warnings and ...
People who are newly diagnosed with knee or hip osteoarthritis continue to take non-steroidal anti-inflammatory drugs (NSAIDs) despite contraindications, a new study shows. A team from Boston ...
The removal of the contraindication to screen for hypersensitivity to blood and blood products is expected to improve workflow efficiency for health care professionals. The Food and Drug ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results